Hirsch, Tobias
Rothoeft, Tobias
Teig, Norbert
Bauer, Johann W.
Pellegrini, Graziella
De Rosa, Laura
Scaglione, Davide
Reichelt, Julia
Klausegger, Alfred
Kneisz, Daniela
Romano, Oriana
Secone Seconetti, Alessia
Contin, Roberta
Enzo, Elena
Jurman, Irena
Carulli, Sonia
Jacobsen, Frank
Luecke, Thomas
Lehnhardt, Marcus
Fischer, Meike
Kueckelhaus, Maximilian
Quaglino, Daniela
Morgante, Michele
Bicciato, Silvio
Bondanza, Sergio
De Luca, Michele
Article History
Received: 19 June 2017
Accepted: 10 October 2017
First Online: 8 November 2017
Competing interests
: G.P. and M.D.L. are co-founders and members of the Board of Directors of Holostem Terapie Avanzate (HTA), s.r.l, Modena, Italy; Chiesi Farmaceutici S.p.A. (a co-founder of HTA), holds an Orphan Drug Medicinal Product designation (EU/3/15/1465) for the transgenic cultures used in this paper.